MedTrace Logo

Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome

NCT04453306 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-07-01

No results posted yet for this study

Summary

Treatment of obesity related to Polycystic Ovary Syndrome with topiramate or placebo to assess improvement of clinical and laboratory parameters after 6 months of follow-up

Conditions

  • Obesity
  • Polycystic Ovary Syndrome
  • Hyperandrogenism

Interventions

DRUG

Topiramate

topiramate 25mg is coated in tablets in an independent laboratory

DRUG

Placebo

innocuous substance is coated in tablets in an independent laboratory

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Poli Mara Spritzer · Federal University of Rio Grande do Sul

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453306 on ClinicalTrials.gov